Once-daily treatment of pulmonary fibrosis

ABSTRACT

A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis.

STATEMENTt REGARDING PRIOR DISCLOSURES by the INVENTOR or a JOINTINVENTOR under 37 C.F.R § 1.77(b)(6)

Summary of Results of Phase Ia data with respect to TD139 was presentedin an on-line Review, Feb. 28, 2015, week of March, p. 16, BioCentuty byGalecto Biotech AB. A copy of the publication will be submitted in aninformation Disclosure Statement, pursuant to the guidance of 78 Fed.Reg. 11076 (Feb. 14, 2013). The summary of results of said Phase Ia datawas obtained from the inventors.

TECHNICAL FIELD

The present invention relates to a compound of formula, (I) for use in amethod for treatment of pulmonary fibrosis in a human, such asIdiopathic pulmonary fibrosis. The invention also relates topharmaceutical compositions comprising the compound of formula (I) foruse in a method for treatment of pulmonary fibrosis in a human.Furthermore the present invention relates to a method for treatment ofpulmonary fibrosis in a human. Moreover, the present invention relatesto a dry powder inhaler device for administration of a compound offormula (I) once-a-day to the narrowest parts of lung tissue of a human.

BACKGROUND ART

Idiopathic pulmonary fibrosis (IPF) represents a massive worldwidehealth burden. It is a chronic condition of unknown etiology in whichrepeated acute lung injury causes progressive fibrosis resulting indestruction of lung architecture, deteriorating lung function withconsequent respiratory failure and death. Although idiopathic pulmonaryfibrosis (IPF) is the archetypal and most common cause of lung fibrosis,numerous respiratory diseases can progress to pulmonary fibrosis, andthis usually signifies a worse prognosis. The median time to death fromdiagnosis is 2.5 years and the incidence and prevalence of IPF continuesto rise. It remains one of the few respiratory conditions for whichthere are no effective therapies, and there are no reliable biomarkersto predict disease progression. The mechanisms resulting in pulmonaryfibrosis are unclear but centre around aberrant wound healing as aconsequence of repetitive epithelial injury from an as yet unknowncause. IPF is characterized by fibroblastic foci containingfibroblasts/myofibroblasts which show increased activation response tofibrogenic cytokines such as transforming growth factor-β1 (TGF-β1),There is a big unmet need for drugs for treatment of Idiopathicpulmonary fibrosis.

SUMMARY OF THE DISCLOSURE

The compound of formula I is a novel, dry powdered inhaled therapy forthe treatment of IPF. Based on results from a first in human study withsingle ascending doses it was concluded that the compound of formula (1)is both safe and well tolerated in man and favorable PK parameterssupport once daily dosing for a specific dose range.

In a first aspect the present invention relates to a compound of formula(I)

for use in a method for treatment of pulmonary fibrosis in a humancomprising administering once-a-day to the narrowest parts of the lungtissue of the human an amount of the compound of formula (I) effectiveto treat said pulmonary fibrosis.

In a further aspect the present invention relates to a pharmaceuticalcomposition comprising a compound of formula (I)

for use in a method for treatment of pulmonary fibrosis in a humancomprising administering once-a-day to the narrowest parts of the lungtissue of the human, the composition comprising an amount of thecompound of formula (I) effective to treat said pulmonary fibrosis.

In a still further aspect the present invention relates to a method fortreatment of pulmonary fibrosis in a human comprising administeringonce-a-day to the narrowest parts of the lung tissue of the human anamount of a compound of formula (I)

effective to treat said pulmonary fibrosis.

In a further aspect the present invention relates to a dry powderinhaler device comprising a compound of formula (I)

for administration once-a-day to the narrowest parts of lung tissue of ahuman of an amount of the compound of formula (I) effective to treatpulmonary fibrosis.

DETAILED DESCRIPTION

The compound of formula (I) has the chemical name (IUPAC) bis(3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl)-β-D-galtactopyranosyl)-sulfane, and as used herein is intended tocover the compound of formula (I) in any possible form, such as solid orliquid, a salt, a solvate, or in free form. The compound of formula (I)may be prepared as described in US2014/0121179 or WO2014/067986.

In one embodiment the compound of formula (I) is bis(3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl)-β-D-galactopyranosyl)-sulfaneas the free form.

In a further embodiment the pulmonary fibrosis is Idiopathic pulmonaryfibrosis (IPF).

In a further embodiment the administration is carried out by a drypowder inhaler. Typically, a single or multiple dose DPI inhaler isused. In one particular embodiment the dry powder inhaler is RS01Monodose Dry Powder Inhaler (Plastiape).

When the compound of formula (I) is formulated as a dry powder it may bepresent in a suitable particle size selected from a mean massaerodynamic diameter (MMAD) between 0.1 and 20 μm, such as a MMADbetween 0.5 and 10 μm, such as between 1 and 5 μm, typically between 2and 3 μm. In the study described in the Experimental section below theMMAD was measured to 2.5 μm. The selected ranges does not exclude thepresence of particles sizes outside these ranges, but the selectedranges are those that provide the desired effect as described herein.

In a still further embodiment the narrowest parts of the lung tissue arethe bronchioles and the alveoli.

In a further embodiment the once daily amount is from 0.15 mg to 50 mg,such as 0.15 mg to 1.5 mg, 1.5 mg to 3 mg, 3 mg to 5 mg, 5 mg to 7 mg, 7mg to 8 mg, 8 mg to 10 mg, 10 mg to 20 mg and 20 mg to 50 mg. Inparticular the once daily amount form 1.5 mg to 20 mg result in aconcentration of the active compound of formula (I) in BAL fluids ormacrophages or both of from 1 nM to 100 μM. More preferredconcentrations of from 10 nM to 10 μM or more preferred 100 nM to 1 μMcan be provided with once daily amount form 3 mg to 10 mg. Based on theresults and studies herein it is predicted that a once daily amount offrom 1.5 mg to 10 mg, such as 2 mg to 7 mg, will provide localconcentrations of the compound of formula I in the lung in a human thatwill be sufficient to suppress Galectin-3 and provide safe and effectivetreatment of pulmonary fibrosis.

In a still further embodiment the treatment is chronic treatment.

The term “treatment” and “treating” as used herein means the managementand care of a patient for the purpose of combating a condition, such asa disease or a disorder. The term is intended to include the fullspectrum of treatments for a given condition from which the patient issuffering, such as administration of the active compound to alleviatethe symptoms or complications, to delay the progression of the disease,disorder or condition, to alleviate or relief the symptoms andcomplications, and/or to cure or eliminate the disease, disorder orcondition as well as to prevent the condition, wherein prevention is tobe understood as the management and care of a patient for the purpose ofcombating the disease, condition, or disorder and includes theadministration of the active compounds to prevent the onset of thesymptoms or complications. The treatment is performed in a chronic way.The patient to be treated is a human subject diagnosed with pulmonaryfibrosis or other types of lung fibrosis.

The term “an amount effective to treat pulmonary fibrosis” of a compoundof formula (I) of the present invention as used herein means an amountsufficient to cure, alleviate or partially arrest the clinicalmanifestations of pulmonary fibrosis and its complications. Effectiveamounts for each purpose will depend on the severity of the disease orinjury as well as the weight and general state of the subject. It willbe understood that determining an appropriate dosage may be achievedusing routine experimentation, by constructing a matrix of values andtesting different points in the matrix, which is all within the ordinaryskills of a trained physician or veterinary.

In a still further aspect the present invention relates to apharmaceutical composition comprising the compound of formula (I) andoptionally a pharmaceutically acceptable additive, such as a carrier oran excipient.

As used herein “pharmaceutically acceptable additive” is intendedwithout limitation to include carriers, excipients, diluents, adjuvant,colorings, aroma, preservatives etc. that the skilled person wouldconsider using when formulating a compound of the present invention inorder to make a pharmaceutical composition.

The adjuvants, diluents, excipients and/or carriers that may be used inthe composition of the invention must be pharmaceutically acceptable inthe sense of being compatible with the compound of formula (I) and theother ingredients of the pharmaceutical composition, and not deleteriousto the recipient thereof. It is preferred that the compositions shallnot contain any material that may cause an adverse reaction, such as anallergic reaction. The adjuvants, diluents, excipients and carriers thatmay be used in the pharmaceutical composition of the invention are wellknown to a person within the art.

As mentioned above, the compositions and particularly pharmaceuticalcompositions as herein disclosed may, in addition to the compoundsherein disclosed, further comprise at least one pharmaceuticallyacceptable adjuvant, diluent, excipient and/or carrier. In oneembodiment the pharmaceutical composition contains neat compound offormula I. In some embodiments, the pharmaceutical compositions comprisefrom 1 to 99 weight % of said at least one pharmaceutically acceptableadjuvant, diluent, excipient and/or carrier and from 1 to 99 weight % ofa compound of formula I as herein disclosed. The combined amount of theactive ingredient and of the pharmaceutically acceptable adjuvant,diluent, excipient and/or carrier may not constitute more than 100% byweight (100% w/w) of the composition, particularly the pharmaceuticalcomposition. In accordance with the present invention the pharmaceuticalcomposition may consist of neat compound of formula I (that is 100% w/wcompound of formula I) or contain a 1-90% w/w, such as 2-20% w/w, forinstance a 3% w/w blend of the compound of formula I.

Typically, the 3% w/w blend is a pharmaceutical composition containing3% w/w compound of formula I and 97% w/w lactose carrier. For theclinical trials a 10% w/w blend is used and consist of a pharmaceuticalcomposition containing 10% w/w compound of formula I and 90% w/w lactosecarrier.

To the person skilled in the art it is well known that particles with amean mass aerodynamic diameter (MMAD) between 0.1 and 20 μm (micrometer) have an increased probability of depositing in the terminalbronchial and alveolar regions. This particle size range is ideal formany indications in pulmonary drug delivery, since a portion of thematerial will still deposit in the upper airways as well. (Cf.Controlled Pulmonary Drug Delivery, Smith and Hickey, Editors, Springer2011, chapter 13).

In accordance with Controlled Pulmonary Drug Delivery, Smith and Hickey,Editors, Springer 2011 in particlular chapters 13, 14 and 15 the skilledperson will know how to formulate compounds, such as the compound offormula (I) for pulmonary drug delivery.

Dry powder inhalers (DPI), such as metered dose medicament inhalers arewell known for dispensing medicament to the lungs of a patient. Someprevious inhalers have comprised a pressurized aerosol dispensingcontainer, wherein the aerosols contain gas propellants in which thepowdered medicament is suspended. Upon actuation, the aerosol contentsare expelled, through a metering valve, and into the lungs of thepatient. Preferred DPIs for use in the present invention is a monodosedry powder inhaler from Plastiape (HQ, Osnago, Italy), in particular theRS01 Monodose Dry Powder Inhaler.

Current designs include pre-metered and device-metered DPIs, both ofwhich can be driven by patient inspiration alone or withpower-assistance of some type. Pre-metered DPIs contain previouslymeasured doses or dose fractions in some type of units (e.g,, single ormultiple presentations in blisters, capsules, or other cavities) thatare subsequently inserted into the device during manufacture or by thepatient before use. Thereafter, the dose may be inhaled directly fromthe pre-metered unit or it may be transferred to a chamber before beinginhaled by the patient. Device-metered DPIs have an internal reservoircontaining sufficient formulation for multiple doses that are metered bythe device itself during actuation by the patient. The wide array of DPIdesigns, many with characteristics unique to the design, will presentchallenges in developing information in support of an application.Regardless of the DPI design, the most crucial attributes are thereproducibility of the dose and particle size distribution. Maintainingthese qualities through the expiration dating period and ensuring thefunctionality of the device through its lifetime under patient-useconditions will probably present the most formidable challenge.

Pressurized Metered-Dose Inhalers (pMDI) may also be suitable deliverydevices for the present compound of formula (I) and are described inControlled Pulmonary Drug Delivery, Smith and Hickey, Editors, Springer2011, chapter 8.

Several types of non-aerosol, breath actuated dry powder inhalers havetherefore been provided. For example, U.S. Pat. No. 5,503,144 to Bacon,shows a breath-actuated dry-powder inhaler. The device includes a drypowder reservoir for containing a dry powdered medicament, a meteringchamber for removal of the powdered medicament from the reservoir indiscrete amounts, and an air inlet for entraining the removed powderedmedicament through a mouthpiece upon patient inhalation.

U.S. Pat. No. 5,458,135 discloses a method and apparatus for producingan aerosolized dose of a medicament for subsequent inhalation by apatient. The method comprises first dispersing a preselected amount ofthe medicament in a predetermined volume of gas, usually air. Thedispersion may be formed from a liquid or a dry powder. The methodrelies on flowing substantially the entire aerosolized dose into achamber that is initially filled with air and open through a mouthpieceto the ambient. After the aerosolized medicament has been transferred tothe chamber, the patient will inhale the entire dose in a single breath.

U.S. Pat. No. 6,065,472 discloses a powder inhalation device comprisinga housing containing a pharmacologically active compound, a conduit withan outlet extending into the housing through which a user can inhale tocreate an airflow through the conduit, a dosing unit for delivering adose of the compound to the conduit and baffles arranged within the saidconduit to aid disintegration of powder agglomerates entrained in saidairflow.

Regardless of whether an aerosol or non-aerosol inhaler is used, it isof utmost importance that particles of the dispensed dry powdermedicament be small enough to ensure the adequate penetration of themedicament into the bronchial region of a patient's lungs duringinhalation. However, because the dry powder medicament is composed ofvery small particles, and often provided in a composition including acarrier such as lactose, non-defined agglomerates or aggregates of themedicament form at random prior to being dispensed. It has thereforebeen found preferably to provide breath-actuated dry powder inhalerswith means for breaking down the agglomerates of medicament ormedicament and carrier before inhalation of the medicament.

Further embodiments of the process are described in the experimentalsection herein, and each individual process as well as each startingmaterial constitutes embodiments that may form part of embodiments.

The above embodiments should be seen as referring to any one of theaspects (such as ‘method for treatment’, ‘pharmaceutical composition’,‘compound for use as a medicament’, or ‘compound for use in a method’)described herein as well as any one of the embodiments described hereinunless it is specified that an embodiment relates to a certain aspect oraspects of the present invention.

All references, including publications, patent applications and patents,cited herein are hereby incorporated by reference to the same extent asif each reference was individually and specifically indicated to beincorporated by reference and was set forth in its entirety herein.

All headings and sub-headings are used herein fix convenience only andshould not be construed as limiting the invention in any way.

Any combination of the above-described elements in all possiblevariations thereof is encompassed by the invention unless otherwiseindicated herein or otherwise clearly contradicted by context.

The terms “a” and “an” and “the” and similar referents as used in thecontext of describing the invention are to be construed to cover boththe singular and the plural, unless otherwise indicated herein orclearly contradicted by context.

Recitation of ranges of values herein are merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range, unless other-wise indicated herein, and eachseparate value is incorporated into the specification as if it wereindividually recited herein. Unless otherwise stated, all exact valuesprovided herein are representative of corresponding approximate values(e.g., all exact exemplary values provided with respect to a particularfactor or measurement can be considered to also pro-vide a correspondingapproximate measurement, modified by “about,” where appropriate).

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext.

The use of any and all examples, or exemplary language (e.g., “such as”)provided herein, is intended merely to better illuminate the inventionand does not pose a limitation on the scope of the invention unlessotherwise indicated. No language in the specification should beconstrued as indicating any element is essential to the practice of theinvention unless as much is explicitly stated.

The citation and incorporation of patent documents herein is done forconvenience only and does not reflect any view of the validity,patentability and/or enforceability of such patent documents.

The description herein of any aspect or embodiment of the inventionusing terms such as “comprising”, “having”, “including” or “containing”with reference to an element or elements is intended to provide supportfor a similar aspect or embodiment of the invention that “consists of”,“consists essentially of”, or “substantially comprises” that particularelement or elements, unless otherwise stated or clearly contradicted bycontext (e.g., a composition described herein as comprising, aparticular element should be understood as also describing a compositionconsisting of that element, unless otherwise stated or clearlycontradicted by context).

This invention includes all modifications and equivalents of the subjectmatter recited in the aspects or claims presented herein to the maximumextent permitted by applicable law.

The present invention is further illustrated by the following examplesthat, however, are not to be construed as limiting the scope ofprotection. The features disclosed in the foregoing description and inthe following examples may, both separately and in any combinationthereof, be material for realizing the invention in diverse formsthereof.

EXPERIMENTAL

The compound of formula I is a novel, inhaled, dry powdered,anti-Galectin 3 small molecule drug therapy being developed for thetreatment of IPF. Here we describe results from the First in Human (FIH)study in healthy male volunteers.

METHODS

This study was a randomized, double-blind, single center,placebo-controlled, single ascending dose (SAD), phase I study to assessthe safety, tolerability, PK (pharmacokinetics) and PD(pharmacodynamics) of the compound of formula I in 36 healthy malevolunteers (HV's). 6 dose cohorts 6 subjects were evaluated using a 4:2ratio (active:placebo). The compound of formula I was delivered to thelungs of HV's using the RS01 Monodose Dry Powder inhaler (Plastiape) atthe following 6 doses: 0.15 mg, 1.5 mg, 3 mg, 10 mg, 20 mg and 50 mg.The 0.15 mg, 1.5 mg and 3 mg dose was a 3% w/w lactose blend, whereasthe 10 mg, 20 me and 50 mg dose was formulated as neat material. Thespecific capsule filling weights were 5 mg for the 0.15 mg dose, 50 mgfor the 1.5 mg dose, 5 mg for the 10 mg dose and 50 mg for the 50 mgdose. HV's were housed overnight and vital signs, EKG, physical exam,urinalysis and laboratory bloods followed for 14 days. PK blood samplingwas taken prior to dosing and then at intervals up to 48 hrs post-dose.Plasma samples for drug concentration measurements were analyzed by theBioanalytical Unit at Simbec (UK). PK variables were determined usingthe non-compartmental analysis option in the software WinNONLIN 6.3 fromCertara based in Princeton, N.J. 08540 (www.eertara.com).

RESULTS

Administration of the compound of formula I was extremely well toleratedat all 6 doses. Adverse events were only mild in nature and includedheadache, cough and dose-related parageusia (neat blend only) all ofwhich were self-limiting. There were no significant changes frombaseline in any of the following parameters; EKG, vital signs, bloodsand urinalysis up to 2 weeks post-dose, The compound of formula I wasrapidly absorbed, with mean tmax values ranging, from 0.8 to 3 hrs,independent of dose. Drug concentrations increased with increasing dose,based on Cmax and AUC and exhibited dose proportionality. t 1/2 is 12hrs. Clearance (CL/F) is high (˜50,000 mL/hr or 900 mL/min) i.e. severalfold higher than renal filtration. Given these findings and thoseconsistent with GLP toxieokinetic studies (˜90% of the compound offormula I following murine intravenous dosing is found in the feces), itis probable that the liver (via bile excretion) is the major route ofelimination in man. Based on radioisotope studies of lung deposition ofthe compound of formula I in mice, whereby concentrations of thecompound of formula I are fifty times greater in the lung than in thecirculation, combined with Cmax data from the 3 mg dose at inhaledconcentrations used in man, local concentrations of the compound offormula I in the lung in man will be 2 fold in excess of those requiredto suppress Galectin-3 in lung target cells based on ex-vivo data ofsuppression of Galectin-3 in human derived macrophages.

CONCLUSION

The compound of formula I is a novel, dry powdered inhaled therapy forthe treatment of IPF. Results from this FIH-SAT) study indicate that thecompound of formula (I) is both safe and well tolerated in man andfavorable PK parameters support once daily dosing. Part II of this studyis ongoing wherein 24 patients with IPF is continually dosed withascending doses (0.15 mg, 1.5 mg, 3 mg, 10 mg, 20 mg and 50 mg) ofonce-daily for 2 weeks with inhaled compound of formula I. Based onthese data the compound of formula I could provide a valuable, safetreatment option for patients with IPF in the future.

We claim:
 1. A method for treatment of pulmonary fibrosis in a humancomprising administering once-a-day to the narrowest parts of the lungtissue of the human an amount of a compound of formula (I)

effective to treat said pulmonary fibrosis, wherein the administrationis carried out by a dry powder inhaler.
 2. The method of claim 1,wherein the compound of formula (I) is bis(3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl)-β-D-galactopyranosyl)-sulfaneas the free form.
 3. The method of claim 1, wherein the pulmonaryfibrosis is Idiopathic pulmonary fibrosis (IPF).
 4. The method of claim1, wherein the administration is carried out by a monodose dry powderinhaler, such as the RS01 Monodose Dry Powder Inhaler (Plastiape). 5.The method of claim 4, wherein the monodose dry powder inhaler is a RS01Monodose Dry Powder Inhaler.
 6. The method of claim 1, wherein the oncedaily amount is from 0.15 mg to 50 mg of the compound of formula I. 7.The method of claim 1, wherein the treatment is chronic treatment. 8.The method of claim 1, wherein the once daily amount is present in asuitable particle size selected from a mean mass aerodynamic diameter(MMAD) between 0.1 and 20 μm.
 9. The method of claim 1, wherein thecompound of formula I is administered neat or together with apharmaceutically acceptable additive.
 10. The method of claim 9, whereinthe pharmaceutically acceptable additive is a carrier.
 11. The method ofclaim 10, wherein the carrier is lactose.